I. L. Ray-Coquard - Concepedia

Author

I. L. Ray-Coquard

Also Known As

Eva María Gómez-García, I Ray-Coquard, I. L. Ray-Coquard, I. Ray-Coquard, I.L. Ray-Coquard, Isabelle Ray-Coquard, Jean-Philippe Spano, Ray-Coquard Isabelle, Ray-Coquard, I, Ray-Coquard, I.

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Centre Léon Bérard Institut Gustave Roussy University College London Université Claude Bernard Lyon 1 Institut Bergonié

About

I. L. Ray-Coquard is an author at Centre Léon Bérard specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	18	1.2K
2	Health Sciences	6	7	195
3	Public Health	1	1	20
4	Emergency Medicine	1	1	51
5	Epidemiology	1	1	20

I. L. Ray-Coquard

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease Nicoletta Colombo, C. Sessa, Andreas du Bois, International Journal of Gynecological Cancer Borderline TumoursTumoral PathologyMedicinePathologyGynecology	2019	385
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial Antoîne Italiano, Olivier Mir, Simone Mathoulin‐Pélissier, The Lancet Oncology Surgical OncologyAdvanced Ewing SarcomaMedicineMetronomic TherapyPharmacotherapy	2020	306
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial Sandro Pignata, Domenica Lorusso, Florence Joly, The Lancet Oncology Carboplatin-based DoubletMedicineMetronomic TherapyGynecologyPlatinum-sensitive Ovarian Cancer	2021	144
Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Sant P. Chawla, Jean‐Yves Blay, I. L. Ray-Coquard, Journal of Clinical Oncology Mtor Inhibitor RidaforolimusAdvanced Sarcoma PatientsPfs EventsMedicinePhase Iii	2011	77
Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: Primary and biomarker analysis of the phase III JAVELIN Ovarian 200 trial Éric Pujade-Lauraine, Keiichi Fujiwara, JA Ledermann, Gynecologic Oncology Biomarker AnalysisMedicineGynecologyLiposomal DoxorubicinTumor Targeting	2019	61
Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5 years of treatment: A French Sarcoma Group Study. I. L. Ray-Coquard, N.B. Bui, Antoine Adenis, Journal of Clinical Oncology Surgical OncologyDisease ProgressionPrognosisPathologyLogistic Analysis	2010	51
Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO (vol 16, pg 566, 2005) Jean‐Yves Blay, Sylvie Bonvalot, Paolo G. Casali, Surgical OncologyGastrointestinal OncologyConsensus MeetingMedicinePg 566	2005	34
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, Gynecologic Oncology Local TherapyMedicineMetronomic TherapyGynecologyParp Inhibitors	2023	32
Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients Pierre-Étienne Heudel, Bertrand Favier, Marie-Laure Solodky, European Journal of Cancer VaccinationVaccine SafetyMedicineCovid-19 PandemicVirology	2022	20
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup Carien L. Creutzberg, Jae‐Weon Kim, Gemma Eminowicz, The Lancet Oncology Consensus RecommendationsEndocrine-related CancerMedicineCancer ManagementGynecology	2024	19

Page 1